MRMichelle Miranda Espejel Romero

Michelle Miranda Espejel Romero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle Miranda Espejel Romero has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Perinatal Mental Healthcare: Screening for Depression and Anxiety, Obstetric Risk Factors, and Continuity of Family-Centered Care

    by Robinson Morey Contreras, Maria Alejandra Cogollo Tarazona, Juan José Vergara Serpa, Michelle Miranda Espejel Romero, Ciro Ernesto Redondo Mendoza, Francisca Javiera Álvarez Alarcón, Jefferson Salguero-Sánchez, Jesús Ricardo Martínez Mota, Norma Janneth Tipán Morales

    Perinatal mental health disorders, particularly depression and anxiety, represent a relevant component of maternal morbidity and may emerge during pregnancy, persist after childbirth, or recur in women with previous psychiatric vulnerability. This study analyzed perinatal mental health from an interdisciplinary perspective, integrating early detection, obstetric and psychosocial risk factors, and continuity of care across gynecology, psychiatry, and family medicine. An integrative literature review based on the Scientific Method was conducted using evidence from clinical guidelines, systematic reviews, meta-analyses, observational studies, and clinical trials. The analysis identified a substantial prevalence of perinatal depression and anxiety, with depressive symptoms affecting approximately one quarter of women in several pooled analyses and anxiety reaching its highest pooled prevalence during the third trimester. The Edinburgh Postnatal Depression Scale demonstrated variable diagnostic performance according to the selected cutoff, highlighting the need to interpret screening within a broader clinical assessment. Obstetric factors also showed relevant associations with maternal mental health, particularly emergency cesarean delivery, which was linked to higher odds of postpartum depression than elective procedures. In addition, collaborative-care interventions showed higher remission rates and greater mental health service utilization than enhanced maternity support alone. These findings indicate that perinatal mental healthcare should not be limited to isolated screening or the immediate postpartum period. A continuous model incorporating validated screening, obstetric and psychosocial risk assessment, timely psychiatric evaluation, treatment, referral, and longitudinal family-centered follow-up may provide a more comprehensive framework for maternal mental healthcare throughout pregnancy and the first postpartum year.

  • Open Access

    Hereditary Gynecologic Cancer Predisposition: Gene-Specific Risk Assessment, Genetic Counseling, and Personalized Prevention Strategies

    by Adriana Patricia Núñez Manohatl, Elsa Noralma Lucas Parrales, Francis Briceida Villanueva Araujo, Michelle Miranda Espejel Romero, Francisca Javiera Álvarez Alarcón, Pablo Eduardo Navarro López, Jefferson Salguero-Sánchez, Paola Alexandra Zambrano Martinez, Gabriela Soraya Vela Lozano, Luis Enrique Ruiz Estrada, et al.

    Hereditary gynecologic cancer syndromes constitute a heterogeneous group of disorders in which pathogenic germline variants increase susceptibility to ovarian, fallopian tube, endometrial, and other related malignancies. This study analyzed current evidence regarding the clinical identification of individuals at increased hereditary risk, molecular testing, genetic counseling, cascade testing, and strategies for cancer risk reduction. A structured integrative review based on the Scientific Method was performed using clinical guidelines, consensus recommendations, prospective cohorts, observational studies, and relevant genetic risk analyses. The results demonstrated substantial gene-specific variability. Cumulative ovarian cancer risk was markedly higher among BRCA1 carriers than among BRCA2 carriers, while moderate-penetrance genes such as BRIP1, RAD51C, and RAD51D showed lower but clinically relevant risk estimates. Lynch syndrome also exhibited heterogeneous gynecologic cancer patterns across MLH1, MSH2, MSH6, and PMS2. The reviewed evidence further identified an important gap between recommendations for genetic evaluation and actual completion of germline or somatic testing in patients with ovarian cancer. Risk-reducing salpingo-oophorectomy was associated with lower ovarian cancer occurrence and reduced cancer-specific and all-cause mortality among selected BRCA1/2 carriers. These findings support an individualized model of hereditary gynecologic cancer management based on integration of clinical history, family history, molecular diagnosis, gene-specific penetrance, genetic counseling, and preventive interventions. Effective hereditary cancer prevention depends not only on identifying pathogenic variants but also on translating genetic information into timely, proportionate, and patient-centered clinical decisions.

  • Open Access

    From Hypertensive Pregnancy to Cardiovascular Prevention: Postpartum Risk Stratification and Long-Term Primary Care

    by Adriana Patricia Núñez Manohatl, Jefferson Salguero-Sánchez, Alberto Macías Rodríguez, Francisca Javiera Álvarez Alarcón, Michelle Miranda Espejel Romero, Pablo Eduardo Navarro López, Dayana Milena Ballesteros Aguay, Jorge Angel Velasco Espinal

    Hypertensive disorders of pregnancy are increasingly recognized as early indicators of long-term maternal cardiovascular vulnerability rather than conditions limited to gestation. This study analyzed the association between hypertensive disorders of pregnancy and subsequent cardiovascular risk, with particular emphasis on postpartum surveillance and preventive strategies within primary care. A structured integrative review based on the Scientific Method was performed using evidence from systematic reviews, meta-analyses, cohort studies, scientific statements, and clinical publications addressing preeclampsia, gestational hypertension, chronic hypertension, cardiovascular outcomes, and postpartum follow-up. The analyzed evidence consistently demonstrated increased risks of chronic hypertension, ischemic heart disease, heart failure, stroke, cardiovascular hospitalization, and cardiovascular mortality after hypertensive pregnancy. Heart failure showed some of the highest relative effect estimates, while chronic hypertension emerged as one of the most frequent and earliest abnormalities identified during follow-up. Recurrent preeclampsia was associated with an even greater cardiovascular burden than a single affected pregnancy, supporting recurrence as a relevant marker for risk stratification. Postpartum studies also showed that hypertension, prediabetes, hyperlipidemia, and type 2 diabetes can be detected within the first years after delivery, particularly when early screening and primary-care follow-up are implemented. These findings support a longitudinal model in which obstetric history is incorporated into cardiovascular prevention, with early postpartum blood pressure assessment, cardiometabolic surveillance, lifestyle intervention, and sustained follow-up through primary care. Coordination between obstetrics and gynecology, family medicine, and cardiology is essential to maintain continuity of care and identify women who may benefit from intensified surveillance. Hypertensive disorders of pregnancy therefore represent an opportunity for early cardiovascular risk recognition and prevention across the maternal life course.

  • Open Access

    CRISPR-Based Genome Editing in Contemporary Clinical Medicine: Therapeutic Translation, Global Challenges and the Future of Precision Medicine

    by Gabriel Alejandro Ortega Moreno, Gerardo Amaya Villagran, Andrés Mauricio Umaña González, Marlies Solís Rodríguez, Gerson Obed Vásquez Sarat, Andres Sebastián Freire Ortega, Juan José Vergara Serpa, Alexa Fernanda Uriostegui Navarro

    CRISPR-based genome editing has transformed the therapeutic possibilities of genomic medicine by enabling programmable modification of disease-associated genes and regulatory pathways. This review analyzed the evolution, current clinical applications, emerging therapeutic strategies, safety limitations, ethical challenges, and future perspectives of CRISPR-based technologies within an international framework that incorporates Latin America. An integrative literature review was conducted using scientific evidence published between 2012 and July 2026, with emphasis on peer-reviewed studies indexed in major biomedical databases and relevant international and regulatory documents. The evidence showed a rapid progression from foundational CRISPR-Cas9 research toward base editing, prime editing, ex vivo cellular modification, and direct in vivo genome editing. Clinical translation was most advanced in hematology, particularly in sickle cell disease and transfusion-dependent β-thalassemia, where genome-edited autologous hematopoietic stem and progenitor cells have demonstrated clinically meaningful therapeutic outcomes. Applications in oncology and hereditary transthyretin amyloidosis further demonstrated the feasibility of engineered immune cells and systemic in vivo genome editing. However, broader clinical implementation remains limited by delivery and tissue targeting, off-target and unintended on-target modifications, immunogenicity, manufacturing complexity, long-term safety, regulatory requirements, and accessibility. The international analysis identified heterogeneous capacity for clinical implementation, emphasizing the need to strengthen genomic infrastructure, population representation, professional training, regulatory preparedness, and research participation in Latin America. CRISPR has therefore progressed from an experimental genome-engineering technology to a clinically relevant therapeutic platform, although its future impact will depend on the ability to combine molecular precision and durable therapeutic benefit with rigorous safety assessment, responsible governance, and equitable access across diverse populations and healthcare systems.

  • Open Access

    A Global Perspective on Hormonal, Dermatologic, and Metabolic Health Across the Female Lifespan

    by Ana Clemente, Antonella Cecilia Alcívar Kuffó, Michelle Miranda Espejel Romero, Stephanie Paola Feijóo Tapia, Fabiola Josselyn Torres Padilla, Dianara Damaris Macias Villa, José Antonio Reyes Pinto, Cesar Martin Gónzalez Rico

    Women’s health has traditionally been approached from a reproductive perspective; however, growing evidence indicates that hormonal changes exert systemic effects extending beyond reproductive function. The present study analyzed hormonal, dermatologic, and metabolic interactions throughout the female lifespan using data obtained from an international population of 12,600 women representing Asia, Europe, North America, South America, Africa, and Oceania. A quantitative, observational, cross-sectional, descriptive-analytical design based on the Scientific Method was employed. Data were collected through anonymous standardized questionnaires that evaluated dermatologic manifestations, metabolic alterations, hormonal changes, and the perceived impact of these conditions on overall health and well-being. The findings demonstrated a high prevalence of dermatologic alterations across all continents, a progressive increase in metabolic changes from puberty to menopause, frequent coexistence of hormonal, dermatologic, and metabolic manifestations, and a consistently high perception of the multidimensional impact of hormonal transitions. These results support the concept that endocrine regulation influences multiple physiological systems simultaneously and reinforce the need for multidisciplinary healthcare approaches that integrate endocrinology, gynecology, dermatology, nutrition, and preventive medicine. The study contributes to the growing international evidence supporting a life-course approach to women’s health beyond reproduction and highlights the importance of comprehensive strategies aimed at improving quality of life and promoting healthy aging.

  • Open Access

    Integrating Precision Oncology, Advanced Imaging, and Palliative Care: A Patient-Centered Framework for Advanced Cancer Management Across the Americas

    by Dra. Susana Sarahí Preciado López, José Antonio Reyes Pinto, Aldo Bolivar Zavala Segovia, Ricardo Daniel Corona González, Gerardo Amaya Villagran, Michelle Miranda Espejel Romero, Edunice Beatriz Mora López, Juan Pablo Monroy Moreno

    Advanced cancer remains a major challenge for healthcare systems worldwide due to its clinical complexity, increasing therapeutic options, and multidimensional patient needs. Recent advances in precision medicine, molecular diagnostics, genomic profiling, advanced radiological technologies, and comprehensive palliative care have transformed the management of patients with advanced malignancies. The objective of this review was to analyze the current evidence regarding the integration of precision medicine, advanced imaging technologies, and comprehensive palliative care in advanced cancer management throughout the Americas. A narrative review based on the Scientific Method was conducted using evidence obtained from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Cochrane Library, and international clinical practice guidelines. The literature was analyzed through thematic synthesis focusing on precision oncology, radiological innovation, patient-centered outcomes, and healthcare implementation. The findings demonstrated that molecular diagnostics, genomic profiling, targeted therapies, immunotherapy, radiomics, and artificial intelligence have significantly improved personalized therapeutic decision-making. Advanced radiological assessment contributes substantially to diagnosis, staging, treatment planning, prognostic evaluation, and response monitoring. Additionally, early integration of palliative care was consistently associated with improved symptom control, quality of life, psychological well-being, communication, and healthcare satisfaction. Important regional differences in access to innovative technologies and specialized supportive care services were identified across the Americas. The evidence supports the development of integrated multidisciplinary models that combine technological innovation with comprehensive supportive care. Such approaches may contribute to improved clinical outcomes, enhanced quality of life, and more equitable cancer care delivery for patients with advanced malignancies.

  • Personalized mRNA Cancer Vaccines: Advancing Precision Oncology Through Neoantigen-Directed Immunotherapy

    by Fabio Camilo Jaramillo Contreras, Marlies Solís Rodríguez, Michelle Miranda Espejel Romero, José Alberto Pérez Pérez, José Antonio Reyes Pinto, Ricardo Harold Flores Arotinco, Jorge Angel Velasco Espinal, Alexa Fernanda Uriostegui Navarro

    Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The emergence of personalized messenger RNA (mRNA)-based cancer vaccines has introduced a novel therapeutic strategy capable of integrating genomic medicine, immunology, and biotechnology into precision oncology. The objective of this review was to analyze the current scientific evidence regarding the biological foundations, immunological mechanisms, clinical applications, advantages, limitations, and future perspectives of personalized mRNA cancer vaccines. A scientific method-based narrative review methodology was employed through a structured search of peer-reviewed literature indexed in PubMed, Scopus, Web of Science, ScienceDirect, SpringerLink, and other internationally recognized databases. The evidence demonstrated that personalized mRNA vaccines can encode patient-specific neoantigens, stimulate robust CD4+ and CD8+ T-cell responses, enhance dendritic-cell-mediated antigen presentation, and promote durable immunological memory. Clinical investigations have reported encouraging results in melanoma, pancreatic cancer, glioblastoma, lung cancer, and other malignancies, particularly when vaccines are combined with immune checkpoint inhibitors. The findings also revealed important advantages, including high therapeutic specificity, individualized treatment design, and rapid development capacity. However, challenges related to neoantigen selection, manufacturing costs, regulatory complexity, and healthcare infrastructure remain significant barriers to widespread implementation. From a regional perspective, countries such as Mexico, Colombia, and Ecuador are progressively expanding precision oncology capabilities, although important limitations persist regarding access to genomic technologies and advanced immunotherapies. Overall, personalized mRNA cancer vaccines represent a promising innovation with the potential to transform future cancer treatment through highly individualized and immune-based therapeutic approaches.